The First School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Oncol Rep. 2018 Aug;40(2):1119-1128. doi: 10.3892/or.2018.6480. Epub 2018 Jun 7.
Ultraconserved regions (UCRs) are 481 segments that have been strictly conserved among many mammalian species for hundreds of years. Their transcribed products belong to long non‑coding RNAs and are closely involved in the progression of various tumors. uc.338 has been reported to promote cell proliferation in hepatocellular and lung cancers. However, the role of uc.338 in colorectal cancer (CRC) proliferation remains unclear. In the present study, we first detected the expression of uc.338 in human tissues and analyzed the relationship between uc.338 expression and clinical features of CRC. We then investigated the biological function of uc.338 in CRC proliferation in vitro and in vivo. Finally, we explored the potential mechanism by which uc.338 promotes the proliferation of CRC cells. Our results indicated that uc.338 was upregulated in CRC tissues and higher uc.338 expression was associated with a larger tumor size, deeper invasion, increased lymph node metastasis and poorer prognosis. Further investigations in vivo and in vitro revealed that uc.338 could promote proliferation and cell cycle G1/S transition, and might target p21 downregulation and cyclin D1 upregulation via the PI3K/AKT pathway in CRC cells. Thus, our findings suggested that uc.338 acts as an oncogene by promoting proliferation in CRC cells, and could become a novel target for CRC detection and therapy.
超保守区域 (UCRs) 是 481 个片段,它们在数百年间在许多哺乳动物物种中严格保守。它们的转录产物属于长非编码 RNA,与多种肿瘤的进展密切相关。uc.338 已被报道可促进肝癌和肺癌中的细胞增殖。然而,uc.338 在结直肠癌 (CRC) 增殖中的作用尚不清楚。在本研究中,我们首先检测了 uc.338 在人组织中的表达,并分析了 uc.338 表达与 CRC 临床特征之间的关系。然后,我们研究了 uc.338 在 CRC 增殖中的体外和体内生物学功能。最后,我们探讨了 uc.338 促进 CRC 细胞增殖的潜在机制。我们的结果表明,uc.338 在 CRC 组织中上调,较高的 uc.338 表达与更大的肿瘤大小、更深的侵袭、更多的淋巴结转移和更差的预后相关。体内和体外的进一步研究表明,uc.338 可通过 PI3K/AKT 通路促进 CRC 细胞的增殖和细胞周期 G1/S 转换,可能通过下调 p21 和上调 cyclin D1 来靶向作用。因此,我们的研究结果表明,uc.338 通过促进 CRC 细胞增殖而发挥癌基因的作用,可能成为 CRC 检测和治疗的新靶点。